Results 11 to 20 of about 4,372,209 (230)
Engineered factor Xa variants retain procoagulant activity independent of direct factor Xa inhibitors [PDF]
Nature Communications, 2017 A major drawback in the clinical use of the oral anticoagulants that directly inhibit factor Xa in order to prevent blood clot formation is the potential for life threatening bleeding events.
Daniël Verhoef +6 more
doaj +2 more sources
Gla-domainless factor Xa: molecular bait to bypass a blocked tenase complex [PDF]
Haematologica, 2012 Background Hemophilia is caused by deficiencies in coagulation factor VIII or IX, resulting in direct blockade of the intrinsic tenase complex and indirect blockade of the extrinsic tenase complex which is rapidly inhibited upon binding of factor Xa to ...
Raphaël Marlu, Benoît Polack
doaj +2 more sources
Pharmacodynamics and Pharmacokinetics of oral factor Xa inhibitors [PDF]
Clinical Pharmacology: Advances and Applications, 2015 Pontus B Persson Institute of Vegetative Physiology, Berlin, GermanyApixaban and rivaroxaban are oral factor Xa inhibitors. In a recent issue of Clinical Pharmacology: Advances and Applications, Frost et al compare apixaban (2.5 mg, twice daily) to ...
Persson PB
doaj +1 more source
Edoxaban: an update on the new oral direct factor Xa inhibitor. [PDF]
, 2014 Edoxaban is a once-daily oral anticoagulant that rapidly and selectively inhibits factor Xa in a concentration-dependent manner. This review describes the extensive clinical development program of edoxaban, including phase III studies in patients with ...
Camm, AJ +5 more
core +1 more source
Haematologica, 2014 Vitamin K-dependent proteases generated in response to vascular injury and infection enable fibrin clot formation, but also trigger distinct immuno-regulatory signaling pathways on myeloid cells.
Eimear M. Gleeson +6 more
doaj +1 more source
Frontiers in Pediatrics, 2021 Objective: The optimal management of anticoagulation in neonatal/pediatric patients during extracorporeal membrane oxygenation (ECMO) has not been established yet and varies greatly among ECMO centers worldwide.
Alba Perez Ortiz +7 more
doaj +1 more source
Discovery and development of Factor Xa inhibitors (2015–2022)
Frontiers in Pharmacology, 2023 As a pathological coagulation process, thrombus can lead to many serious diseases, including ischemic stroke, acute myocardial infarction (AMI), acute coronary syndrome (ACS), and deep venous thrombosis (DVT).
Wei Zheng +5 more
doaj +1 more source
The role of factor Xa inhibitors in venous thromboembolism treatment [PDF]
, 2015 Katherine P Cabral,1 Jack E Ansell2 1Department of Pharmacy Practice, Albany College of Pharmacy and Health Sciences, Albany, NY, USA; 2Hofstra-North Shore/LIJ School of Medicine, Hempstead, NY, USA Abstract: Three factor Xa inhibitors have been studied
Ansell, J. E. +3 more
core +1 more source
Heavy menstrual bleeding on direct factor Xa inhibitors: Rationale and design of the MEDEA study
Research and Practice in Thrombosis and Haemostasis, 2021 Background In premenopausal women, treatment with direct oral factor Xa inhibitors is associated with an increased risk of heavy menstrual bleeding (HMB) compared with vitamin K antagonists (VKA).
Eva N. Hamulyák +18 more
doaj +1 more source
TH Open, 2018 Rivaroxaban and apixaban are both small molecules that reversibly inhibit factor Xa. Compared with rivaroxaban, apixaban has minimal effects on the prothrombin time and activated partial thromboplastin time.
Paul Y. Kim +7 more
doaj +1 more source